EMA sets June target for finalizing trial data disclosure policy
This article was originally published in SRA
Executive Summary
In an attempt to assuage pharmaceutical industry fears about the disclosure of commercially confidential information (CCI), the European Medicines Agency is looking at the best way of deleting such information from clinical trial data that would be released under the agency's controversial draft policy on proactive disclosure1,2. The EMA says it plans to present the final policy together with an implementation plan to its management board for endorsement at the next meeting of the board in June.